TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05123209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM83 CAR-T cells
Description: 3×10\^9 CAR-T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM83 CAR-T cells
Description: 3×10\^9 CAR-T cells

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The second-line treatment of liver cancer
Description: approved by NMPA
Study: NCT04190550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO
Study: NCT05512988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course
Study: NCT04546178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE)+ therapy
Description: The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
Study: NCT06464055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation
Description: GQ1010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion1
Description: GQ1010 dose1
Study: NCT06460103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of a Straumann® Bone Level Tapered implant SLActive® (hydrophilic surface)
Description: Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLActive® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a Straumann® Bone Level Tapered implant SLA® (hydrophobic surface)
Description: Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLA® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.
Study: NCT06464055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion2
Description: Drug: GQ1010 dose2
Study: NCT05513222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flipped autograft
Description: Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
Study: NCT06464055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phase II
Description: Drug: GQ1010 RP2D
Study: NCT05549843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Each session will last approximately 50-60 minutes, with 1 physiotherapy session per week over a period of 3 weeks. Each session is made up of 10 steps, of which 9 correspond to manual interventions commonly used in the field of manual therapy.
Study: NCT04971382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
Study: NCT06067074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar Locking Plate
Description: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaster Cast
Description: Non-operative treatment with a plaster cast
Study: NCT05311215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-1002
Description: SL-1002 injectable solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo injectable solution
Study: NCT05605418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS intervention
Description: The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
Study: NCT06209580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-253 for injection
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-253 for injection
Description: Administered intravenously
Study: NCT05517707

Intervention type: DEVICE
Intervention: Nasogastric Tube
Description: Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
Study: NCT04666649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax and pegcrisantaspase
Description: Therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax and pegcrisantaspase
Description: Therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax and pegcrisantaspase
Description: Therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax and pegcrisantaspase
Description: Therapeutic
Study: NCT05307874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT01
Description: anti-BTN3A mAb IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT01
Description: anti-BTN3A mAb IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT01
Description: anti-BTN3A mAb IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT01
Description: anti-BTN3A mAb IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT01
Description: anti-BTN3A mAb IV Q3W
Study: NCT04889560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Home-based version of a computerized cognitive training (CoRe)

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Computerized cognitive training (CoRe)
Study: NCT06198439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Magstim Rapid2 Therapy System
Study: NCT05477823

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Standard of care EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate brachytherapy boost
Description: Standard of care BTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Standard of care ADT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)/magnetic resonance imaging (MRI)
Description: Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
Study: NCT05367453

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tropical juice with probiotics (B.coagulans)
Description: Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a Tropical juice with no probiotics
Description: Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lactase tablet
Description: lactase tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo tablet (cornstarch)
Description: placebo tablet (cornstarch)
Study: NCT06539390

Intervention type: OTHER
Intervention: Transforaminal Epidural Injections?
Description: Pain, lumbar disc herniation,Transforaminal Epidural Injections?
Study: NCT05257538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FMT
Description: Fecal microbiota transfer from a healthy and tested volunteer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo enema
Description: colored water enema
Study: NCT04654689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomed polyphenols resveratrol and curcumin
Description: Combination of resveratrol (75mg) and curcumin (200mg) liposomed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for liposomed resveratrol and curcumin
Description: Water with sucrose replacing the liposomed polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric Diet
Description: 40% carbohydrates, 40% lipids and 20% proteins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric Diet
Description: 40% carbohydrates, 40% lipids and 20% proteins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G04CB02
Description: G04CB02, in a single daily dose for 4 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo microcrystalline methylcellulose
Description: Placebo replacing G04CB02
Study: NCT05558410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT05809453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
Study: NCT05550025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab& apatinib
Description: TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear.
Study: NCT05659264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-0184
Description: mRNA-0184 dispersion for intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-0184
Description: mRNA-0184 dispersion for intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05254379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session.
Study: NCT06573788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet + wearble device multimodal prehabilitation
Description: Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional multimodal prehabilitation
Description: The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
Study: NCT06457152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-Emedded Alert
Description: For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
Study: NCT05565612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normodigest Classic
Description: Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compound based on maltodextrin and other excipients
Study: NCT05611528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: Evinacumab 15 mg/kg administered intravenously every 4 weeks
Study: NCT05068765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication skills psychoeducation
Description: Intervention explanations are explained in the groups section.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General psychoeducation
Description: İntervention descriptions are explained in the intervention groups section.
Study: NCT06055322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Dialectical Behavior Therapy
Description: DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
Study: NCT05307874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT01
Description: anti-BTN3A mAb IV Q3W
Study: NCT05286918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The intervention (CRP-guided) group
Description: The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days).
Study: NCT06132100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digitalized incentive spirometry
Description: digitalized incentive spirometry

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: traditional incentive spirometry
Description: traditional incentive spirometry
Study: NCT06300541

Intervention type: PROCEDURE
Intervention: Colectomy
Description: Observational study.

Intervention type: PROCEDURE
Intervention: Colectomy
Description: Observational study.
Study: NCT05481112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Buprenorphine Injection
Description: Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Buprenorphine Injection
Description: Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
Study: NCT05890027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Ophthalmic
Description: One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eyelid Tape
Description: Participants will have the affected eye with ptosis manually lifted using tape.
Study: NCT05693922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC
Description: Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Single-session behavioral activation
Description: Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities
Study: NCT05282810

Intervention type: OTHER
Intervention: tympanoplasty
Description: use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
Study: NCT05307874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin Injectable Product
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin Injectable Product
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles
Study: NCT04649892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
Study: NCT05307874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin Injectable Product
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles
Study: NCT04649892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational
Description: Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
Study: NCT05307874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin Injectable Product
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin Injectable Product
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin Injectable Product
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin Injectable Product
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: 200mg administered following ICT01 + LDSC IL-2 over 30 min Q3W